![]() ![]() Responsiveness was assessed in the subset of patients who developed a urinary tract infection (UTI) during the trial using the standardized response mean (SRM). Discriminant validity was determined by comparing participants with paraplegia and tetraplegia using the effect size (ES). Subjects were administered the standard SF-36 plus three additional questions, in which ‘walk’ was replaced with ‘wheel’ for three of the physical function (PF) questions. SF-36 scores collected at baseline and on completion of a randomized controlled trial in 305 patients with SCI and neuropathic bladder. The SF-36 is one of the components of the MSQLI as well as the MSQOL-54 and was included in these instruments to serve as a generic health-related quality of life measure that could provide a basis for comparison between the MS patients and other populations.To evaluate the validity and responsiveness of a modified SF-36 within a spinal cord-injured (SCI) population. The two summary scores are the physical component summary and the mental component summary. The 8 subscales are: physical functioning, role limitations due to physical problems, bodily pain, general health perceptions, vitality, social functioning, role-limitations due to emotional problems, and mental health. There is no single overall score for the SF-36, instead, It generates 8 subscales and two summary scores. This instrument addresses health concepts that are relevant to MS patients from the patient's perspective. Population-based normative data on the SF-36 is available for the United States and some other countries as well. The SF-36 has also demonstrated sensitivity to significant treatment effects in a variety of patient populations. It is one of the most widely used generic measures of health-related quality of life and has been shown to discriminate between subjects with different chronic conditions and between subjects with different severity levels of the same disease. The Short Form-36 was derived from the General Health Survey of the Medical Outcomes Study by Stewart and colleagues (1988). d Disease Modifying Therapy Guidance During COVID-19.COVID-19 Vaccines for Children and Adolescents with MS and Related Disorders.Timing MS Medications with COVID-19 Vaccines.d COVID-19 Vaccine Guidance for People Living with MS.Resources and Services for Your Patients.Scientific Peer Reviewers & Advisory Committees.Independent Review of Society's Research Programs.d Social Media Fundraisers: Network for a Cure.Research Studies: Newly Diagnosed with MS.COVID-19 Studies Recruiting People with MS.Families Affected by Multiple Sclerosis.Multiple Sclerosis and the Americans with Disabilities Act (ADA).d Emotional Well-Being and Multiple Sclerosis.d Find Programs & Services in Your Area.Brain Chat With the Nerdy Neurologist Podcast.Resilience: Addressing the Challenges of MS.d aHSCT in MS (Autologous Hematopoietic Stem Cell Transplantation).d Complementary and Alternative Medicines and Multiple Sclerosis.Functional Electrical Stimulation (FES) and Multiple Sclerosis.Make the Most of Your Healthcare Provider Visits.New to Pediatric MS: Navigating Your Journey.Neuromyelitis Optica Spectrum Disorder (NMOSD). ![]() Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD).Acute Disseminated Encephalomyelitis (ADEM).How Multiple Sclerosis Affects the Black Community.Primary Progressive Multiple Sclerosis (PPMS).Secondary Progressive Multiple Sclerosis (SPMS).Relapsing-remitting Multiple Sclerosis (RRMS). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |